Literature DB >> 9741350

Soluble Fas mRNA is dominantly expressed in cases with silicosis.

T Otsuki1, H Sakaguchi, A Tomokuni, T Aikoh, T Matsuki, Y Kawakami, M Kusaka, H Ueki, S Kita, A Ueki.   

Abstract

Although it is well known that cases with silicosis exhibit various immunological abnormalities, the mechanisms involved in the occurrence of immuno-dysfunction or dysregulation induced by silica compounds have not yet been determined. Fas is a well-known cell surface molecule that is involved in the apoptosis pathway that belongs to the tumour necrosis factor-receptor family. Soluble Fas (sFas) is produced as an alternatively spliced product of the Fas gene and protects cells from apoptosis due to antagonization of the binding between membrane form of the Fas gene (mFas) and the Fas ligand. To determine the role of the Fas/Fas ligand system in silica-induced immunological abnormalities, we investigated Fas and Fas-ligand message expression levels using the multiplex reverse transcription-polymerase chain reaction (RT-PCR) method with peripheral blood mononuclear cells from silicosis cases with no clinical symptoms of autoimmune diseases. Although the relative expression levels of the Fas or Fas-ligand genes were not remarkably altered in these cases, we observed the sFas message was dominantly expressed compared with mFas expression. These results suggest that self-recognizing clones in cases with silicosis survive for decades, escaping the exclusion mechanisms induced by apoptosis. Then they cause the appearance of autoantibodies and the acquisition of autoimmune diseases sequentially.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741350      PMCID: PMC1364214          DOI: 10.1046/j.1365-2567.1998.00509.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Scleroderma in goldminers on the Witwatersrand with particular reference to pulmonary manifestations.

Authors:  L D ERASMUS
Journal:  S Afr J Lab Clin Med       Date:  1957-09

2.  Elevated levels of soluble Fas in systemic lupus erythematosus: comment on the article by Knipping et al.

Authors:  M Okubo; H Ishida; R Kasukawa
Journal:  Arthritis Rheum       Date:  1996-09

3.  Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.

Authors:  S Jodo; S Kobayashi; N Kayagaki; N Ogura; Y Feng; Y Amasaki; A Fujisaku; M Azuma; H Yagita; K Okumura; T Koike
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

4.  A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen.

Authors:  N Itoh; S Nagata
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

5.  An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.

Authors:  G Papoff; I Cascino; A Eramo; G Starace; D H Lynch; G Ruberti
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

6.  Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.

Authors:  E Knipping; P H Krammer; K B Onel; T J Lehman; E Mysler; K B Elkon
Journal:  Arthritis Rheum       Date:  1995-12

7.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

8.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

Review 9.  Fas and Fas ligand: lpr and gld mutations.

Authors:  S Nagata; T Suda
Journal:  Immunol Today       Date:  1995-01

10.  The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis.

Authors:  G P Rodnan; T G Benedek; T A Medsger; R J Cammarata
Journal:  Ann Intern Med       Date:  1967-02       Impact factor: 25.391

View more
  19 in total

1.  Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.

Authors:  T Otsuki; A Tomokuni; H Sakaguchi; T Aikoh; T Matsuki; Y Isozaki; F Hyodoh; H Ueki; M Kusaka; S Kita; A Ueki
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Serum levels of soluble Fas ligand in patients with silicosis.

Authors:  A Tomokuni; T Otsuki; Y Isozaki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.

Authors:  Shuko Murakami; Yasumitsu Nishimura; Megumi Maeda; Naoko Kumagai; Hiroaki Hayashi; Ying Chen; Masayasu Kusaka; Takumi Kishimoto; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2009-03-18       Impact factor: 3.674

4.  Detection of anti-topoisomerase I autoantibody in patients with silicosis.

Authors:  Akiko Tomokuni; Takemi Otsuki; Haruko Sakaguchi; Yumika Isozaki; Fuminori Hyodoh; Masayasu Kusaka; Ayako Ueki
Journal:  Environ Health Prev Med       Date:  2002-04       Impact factor: 3.674

5.  Lymphopenia in occupational pulmonary silicosis with or without autoimmune disease.

Authors:  J F Subra; G Renier; P Reboul; F Tollis; R Boivinet; P Schwartz; A Chevailler
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 6.  Silica exposure and altered regulation of autoimmunity.

Authors:  Suni Lee; Hidenori Matsuzaki; Naoko Kumagai-Takei; Kei Yoshitome; Megumi Maeda; Ying Chen; Masayasu Kusaka; Kozo Urakami; Hiroaki Hayashi; Wataru Fujimoto; Yasumitsu Nishimura; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2014-08-19       Impact factor: 3.674

7.  Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis.

Authors:  Akiko Takata-Tomokuni; Ayako Ueki; Mieko Shiwa; Yumika Isozaki; Tamayo Hatayama; Hironobu Katsuyama; Fuminori Hyodoh; Wataru Fujimoto; Hiroaki Ueki; Masayasu Kusaka; Hisashi Arikuni; Takemi Otsuki
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

8.  An overview of caspase: Apoptotic protein for silicosis.

Authors:  Rajani G Tumane; Shubhangi K Pingle; Aruna A Jawade; Nirmalendu N Nath
Journal:  Indian J Occup Environ Med       Date:  2010-08

9.  Occupational silica exposure as a risk factor for scleroderma: a meta-analysis.

Authors:  Zachary D McCormic; Sura S Khuder; Bishwa K Aryal; April L Ames; Sadik A Khuder
Journal:  Int Arch Occup Environ Health       Date:  2010-01-03       Impact factor: 3.015

Review 10.  Environmental factors and human health: fibrous and particulate substance-induced immunological disorders and construction of a health-promoting living environment.

Authors:  Takemi Otsuki; Hidenori Matsuzaki; Suni Lee; Naoko Kumagai-Takei; Shoko Yamamoto; Tamayo Hatayama; Kei Yoshitome; Yasumitsu Nishimura
Journal:  Environ Health Prev Med       Date:  2015-12-11       Impact factor: 3.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.